PMID: 9160032May 1, 1997Paper

Intraoperative mitomycin in primary pterygium excision. A prospective, randomized trial

Ophthalmology
C A ManningR W Yee

Abstract

Conjunctival autograft transplantation and postoperative mitomycin therapy are two adjuvant treatment methods shown to lessen the high pterygium recurrence rate seen with simple excision alone. The authors conducted a prospective, randomized study comparing these two techniques with a relatively new treatment method using intraoperative mitomycin application. Fifty patients with 56 primary pterygia were randomized to 1 of 3 treatment groups: conjunctival autograft (group 1), postoperative mitomycin 0.2 mg/ml four times a day x 7 days (group 2), and intraoperative mitomycin 0.4 mg/ml x 3 minutes (group 3). The mean follow-up time was 16 months (range, 6 to 28 months). Recurrences developed in 4 (22.2%) of 18 eyes in group 1, 4 (21.1%) of 19 eyes in group 2, and 2 (10.5%) of 19 eyes in group 3. Complications developed in two, patients from group 2, scleral thinning managed successfully with a scleral patch graft, and epithelial toxicity that resolved on discontinuation of mitomycin on postoperative day 6. There were no complications in the other two groups. Intraoperative mitomycin is a simple and effective alternative to postoperative mitomycin therapy, showing the lowest recurrence rate in their series with no toxicity during t...Continue Reading

References

Nov 1, 1992·Ophthalmology·R S RubinfeldM G Speaker
Dec 15, 1988·American Journal of Ophthalmology·S HayasakaT Setogawa
Jun 1, 1988·Ophthalmology·G SinghC S Foster
Nov 1, 1985·Ophthalmology·K R KenyonM E Hettinger
Aug 1, 1995·American Journal of Ophthalmology·P P ChenP J McDonnell
Apr 1, 1994·Ophthalmology·L W HirstD Chant
Jul 1, 1993·Ophthalmology·G Singh
Nov 1, 1953·American Journal of Ophthalmology·J W ROSENTHAL
Jul 1, 1949·American Journal of Ophthalmology·H S SUGAR

❮ Previous
Next ❯

Citations

Apr 19, 2005·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Arno HueberMichael Diestelhorst
Nov 16, 2004·Eye·M FernandesG N Rao
Oct 14, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sameh S MandourHala M Mohamed
Aug 6, 2000·Cornea·A C YanyaliY Caglar
Jun 4, 2008·Cornea·Rahamim AvisarDov Weinberger
Sep 23, 2009·Cornea·Consuelo Pérez-RicoMiguel Angel Teus
Jan 7, 2009·International Ophthalmology Clinics·Amit Todani, Samir A Melki
Jun 5, 2013·International Ophthalmology·Sekelj SandraAric Ivana
Dec 12, 2013·Cornea·Qiongwen HuYongping Ma
Jul 25, 2012·Indian Journal of Ophthalmology·Khaled S Zaky, Yasser M Khalifa
Jun 6, 2000·The British Journal of Ophthalmology·S AmanoK Eguchi
Jun 15, 2007·Current Opinion in Ophthalmology·Leonard P K AngDonald T H Tan
Jun 23, 2010·Archivos de la Sociedad Española de Oftalmología·J Benítez-HerrerosM A Teus-Guezala
May 18, 2006·Acta Ophthalmologica Scandinavica·Takahiro NakamuraShigeru Kinoshita
Feb 27, 2015·Cornea·T Peter Lindquist, W Barry Lee
Apr 6, 2005·American Journal of Ophthalmology·Leonard P K AngRoger W Beuerman
Nov 11, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sameh S MandourRokia A Sakr
Dec 22, 2006·Expert Opinion on Drug Safety·Ali A Mearza, Ioannis M Aslanides

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.